In:
The Pharmacogenomics Journal, Springer Science and Business Media LLC, Vol. 22, No. 2 ( 2022-03), p. 117-123
Abstract:
The study of sex-specific genetic associations with opioid response may improve the understanding of inter-individual variability in pain treatments. We investigated sex-specific associations between genetic variation and opioid response. We identified participants in the RIGHT Study prescribed codeine, tramadol, hydrocodone, and oxycodone between 01/01/2005 and 12/31/2017. Prescriptions were collapsed into codeine/tramadol and hydrocodone/oxycodone. Outcomes included poor pain control and adverse reactions within six weeks after prescription date. We performed gene-level and single-variant association analyses stratified by sex. We included 7169 non-Hispanic white participants and a total of 1940 common and low-frequency variants (MAF 〉 0.01). Common variants in MACROD2 (rs76026520), CYP1B1 (rs1056837, rs1056836), and CYP2D6 (rs35742686) were associated with outcomes. At the gene level, FAAH , SCN1A , and TYMS had associations for men and women, and NAT2 , CYP3A4 , CYP1A2 , and SLC22A2 had associations for men only. Our findings highlight the importance of considering sex in association studies on opioid response.
Type of Medium:
Online Resource
ISSN:
1470-269X
,
1473-1150
DOI:
10.1038/s41397-022-00265-9
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
2051501-7
SSG:
15,3
Permalink